The startup has developed a scalable purification platform that removes unwanted cells from stem cell products, addressing the critical issue of cellular impurities in cell therapy manufacturing. By utilizing deep analytics and a flexible workflow, the platform ensures the production of safer, higher-quality stem cell therapies in any laboratory setting.
Funding
$200K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cellular impurities in stem cell products pose a significant challenge in cell therapy manufacturing, potentially compromising the safety and efficacy of treatments. Current methods for removing unwanted cells can be inefficient, inconsistent, and difficult to scale across different laboratory settings. This can lead to delays in development and increased costs for producing high-quality stem cell therapies.
Solution
The company offers a scalable purification platform designed to remove unwanted cells from stem cell products, addressing a critical bottleneck in cell therapy manufacturing. By leveraging deep analytics, the platform precisely identifies impurities within stem cell products. A flexible workflow allows seamless integration with diverse starting materials in various laboratory environments. The platform creates and validates a custom component to include during differentiation, which removes impurities, resulting in a purified product.
Target Audience
The primary target audience includes researchers, manufacturers, and clinical developers involved in stem cell therapy production who require efficient and reliable methods for removing cellular impurities.
Features
- Deep analytics to pinpoint impurities in stem cell products
- Flexible workflow that integrates with diverse starting materials
- Custom component design and validation for impurity removal during differentiation
- Scalable process for producing safer, higher-quality products